Osaka University Venture Capital joins RegCell USD 44 million Series A round

• Osaka University Venture Capital invested additional capital in RegCell’s Series A round, taking its total Series A commitment to about USD 3 million.
• RegCell raised about USD 44 million in the Series A, led by Playground Global, with participation from new and existing investors.
• RegCell is an Osaka University spinout developing autoimmune disease cell therapies using regulatory T cells, based on Shimon Sakaguchi’s research.
• Proceeds earmarked to advance clinical development of S/F-Epigen Treg programs, expand indications, develop next-generation epigenetic reprogramming technology.
• RegCell also expects up to about JPY 3.4 billion in additional support from Japan’s AMED, implying up to about USD 66 million total funding.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Osaka University Venture Capital Co Ltd published the original content used to generate this news brief on September 24, 2026, and is solely responsible for the information contained therein.